The National Institute for Health and Care Excellence (NICE) in the UK has released draft guidance proposing the introduction of two new non-invasive tests to significantly shorten the time it takes to diagnose endometriosis. These tests, Endotest and Endosure, are slated for a three-year trial period by General Practitioners (GPs) in England and Wales, with the aim of gathering data on their effectiveness.
Endometriosis is a condition where tissue similar to the lining of the womb grows outside of it, leading to symptoms such as severe pelvic pain, heavy periods, fatigue, and infertility. It affects approximately one in 10 women. Despite its prevalence, many individuals experience years of diagnostic delays, often leading them to minimize their symptoms.
Abbie Filer, a 27-year-old who was diagnosed with endometriosis in 2024 after a decade of symptoms, shared her experience. She described minimizing her pain and the challenges of seeking help. Filer's own diagnosis was delayed until she experienced urinary retention, requiring surgery for confirmation. "If I hadn't gone into urinary retention, I probably wouldn't have a diagnosis at this point in time," she stated.
The proposed Endotest is a spit test designed to detect genetic material, while Endosure utilizes sensor pads on the abdomen to measure electrical signals in the gut. These tests are intended to be offered by GPs during the trial period to collect evidence on their success and impact.
While patient advocacy groups have welcomed the proposed changes, some emphasize that further efforts are needed to address the long-standing issues surrounding endometriosis diagnosis and care. The current diagnostic pathway often involves extensive waiting periods and invasive procedures.